SUMMARY
INTRODUCTION
Lyme borreliosis is an infectious disease caused by the spirochete bacterium Borrelia burgdorferi, a gram negative, microaerophilic rod belonging to the family Spirochaetaceae. Borrelia is transmitted by the bite of ticks, in central Europe mainly by the species Ixodes ricinus. During the blood meal of the ticks, Borrelia migrates from the gut into the salivary glands and from there into the host tissue where it multiplies and also disseminates via blood and lymph fluid. In contrast to the US, where mainly one species Borrelia burgdorferi sensu stricto is responsible for Borrelia infections, there are at least 3 diagnostically relevant genospecies in central Europe: Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii. Depending on the geographical region further genospecies such as Borrelia spielmanii or Borrelia bavariensis may occur [1] [2] [3] . The course of Lyme borreliosis may vary from asymptomatic to acute or chronic infections and is divided into 3 stages with respect to the time interval from the day of the tick bite. Characteristic clinical manifestations in the different stages can be but are not restricted to: erythema migrans (stage I, days to weeks after the tick bite), myositis, arthritis, myalgia and, less frequently, meningoradiculitis, meningoradiculoneuritis (Bannwarth syndrome), meningitis, encephalitis, pericarditis (stage II, weeks to six months after the tick bite), and oligoarthritis, acrodermatitis chronica atrophicans, polyneuropathy and less frequently encephalitis, and encephalomyelitis (stage III, 6 months to years after the tick bite) [9] . Diagnosis of Lyme borreliosis and the following decision for treatment are mainly based on clinical findings that are confirmed by serological methods for detection of Borrelia specific antibodies in serum samples of the respective patients. The difficulties of serological Borrelia diagnosis are due to the heterogeneity of the pathogen and some of its diagnostically relevant surface proteins, since their expression varies during the course of the infection and depends on external factors such as antibiotic therapy. The diagnostic gap of 2 -3 weeks between tick bite and detectable antibody titers in patients´ serum samples should also be considered. Despite these difficulties serology has proven a reliable tool for confirming or excluding Lyme borreliosis. The recommended two-step testing comprises a first sensitive screening ELISA for detection of IgM and IgG antibodies followed by a Western blot or Line Immunoassay as confirmatory test in case of a positive screening result [5] . However, the diagnostic suitability of this procedure is disputed since numerous examples from laboratory practice indicate that the screening tests are not always more sensitive than the confirmatory tests as the essential prerequisite for such a recommendation. The introduction of and restriction to Borrelia specific and diagnostically relevant recombinant proteins in the production of Line immunoassays has further improved this procedure. Despite some improvements, Line immunoassays are still not fully automatable and therefore of limited suitability for higher sample throughput. Nearly ten years ago, multiplex assays based on bead technology in combination with fluorescence measurement were introduced into the serodiagnosis of Lyme disease [13] . These tests are automated and enable high throughput testing. The susceptibility of the measurement technique to disturbances and the high instrument, reagent and maintenance costs have hampered a wide-spread acceptance of these techniques up to now.
MATERIALS AND METHODS

Serum samples
For determination of sensitivity, 370 anonymized serum samples derived from outpatients with suspected Lyme borreliosis were collected for this retrospective study. For determination of specificity, 150 anonymized samples from healthy blood donors from North RhineWestfalia (Haema GmbH) as well as 30 rheumatoid factor (RF) positive sera, 51 antinuclear antibodies (ANA) positive sera, and 23 Epstein-Barr-Virus (EBV) positive sera (collected at the Institut für Medizinische Diagnostik MVZ GbR, Berlin) were included in this comparative study. All samples were tested in parallel with the new microspot-based multiplex array SeraSpot ® Anti-Borrelia IgG/IgM and the bead-based multiplex assay recomBead ® Borrelia IgG/IgM.
SeraSpot
® Anti-Borrelia IgG/IgM Recombinant, Borrelia specific antigens are directly adsorbed as distinct spots on the bottom of the wells of microtitration plates (Figure 1 
Precision analysis of SeraSpot
® Anti-Borrelia under routine conditions Samples of known antibody titers for different Borrelia specific antigens were tested to cover the entire parameter and measuring range. The intraassay precision CV was calculated from 8-fold determination of samples in one test run. Interassay precision CV was calculated by 2-fold determination of samples in 10 different test runs on 3 consecutive days. Lot-to-lot reproducibility was tested with 3 different production lots by running samples in 2-fold determination in 9 test runs on 3 consecutive days.
Influence of potentially interfering substances
Samples of known antibody titers for different Borrelia specific antigens were spiked with potentially interfering substances to final concentrations (bilirubin F 1.97 -19.7 mg/dL, bilirubin C 2.1 -21.0 mg/dL, hemoglobin 50 -500 mg/dL, lipid factor 0.1 -1.0%, and rheumatoid factor 250 -459 U/mL) and tested in the SeraSpot ® Anti-Borrelia IgG/IgM assays in comparison to the respective samples without spiking.
Statistics
Coefficient of correlation r 2 was calculated using SigmaPlot software.
RESULTS
Sensitivity (detection of IgG antibodies)
Out of the 370 samples from patients with suspected borreliosis 194 were concordantly determined positive, 139 negative, and 1 equivocal for IgG antibodies resulting in an overall concordance of 90.3% ( ® results were all due to a single positive VlsE reaction and different result interpretation, although VlsE was positive or borderline in both assays. Eight out of the 11 recomBead ® negative but SeraSpot ® positive samples were characterized by reactivity with OspC in combination with VlsE and/or p58 (n = 3) or by p18 in combination with VlsE (n = 4). In contrast to SeraSpot ® , 4 samples were evaluated as positive in the recomBead ® test due to reactivity with OspC in combination with either VlsE or p58 and/or p100. A total of 7 samples were determined positive in the recomBead ® test by combination of VlsE with p100 and/ or p58. The same samples were judged borderline by the SeraSpot ® test due to missing p100 and/or p58 reactivity.
Sensitivity (detection of IgM antibodies)
For IgM antibody detection, the overall concordance of the two methods was 89.5% (331/370) with 152 positive, 1 borderline, and 178 negative samples (Table 2) . SeraSpot ® determined 23 IgM positive and 7 IgM borderline samples which showed a negative result in the recomBead® test and 9 SeraSpot ® negative samples reacted positive (8) either OspC (n = 5), OspC in combination with p18 (n = 2) or to p100 and VlsE (n = 1). All samples were confirmed negative by Seraline ® Line Immunoassay, one sample also by recomLine ® Line immunoassay (data not shown).
Specificity
Diagnostic specificity of the SeraSpot ® and recomBead ® assay was comparable in the different sample panels. Values in blood donor, RF, ANA, and EBV serum samples ranged between 90% and 100% (Table 3) .
Precision
Analysis of within-run and between-run precision calculated as intra-and interassay coefficients of variation (CV) resulted in values between 1.5 and 8.2% for IgG and between 2.1 and 8.6% for IgM antibody detection and for the different Borrelia antigens and different signal intensities (Table 4) . The values are comparable to CVs usually measured in established ELISA tests and are below the acceptable limit of 10% and 15% for intra-and interassay CV, respectively. The lot-to-lot reproducibility delivered CVs below 15% for both SeraSpot ® Anti-Borrelia IgG and SeraSpot ® Anti-Borrelia IgM at an acceptance limit of 20% ( Table  5 ).
The CV for the cutoff spot representing low signal intensities with usually higher imprecision were calculated 4.3% (intraassay), 10.0% (interassay), and 12.5% (lot-to-lot) for IgG detection and 4.7% (intraassay), 3.8% (interassay), and 8.6% (lot-to-lot) for IgM detection, thus fulfilling the specifications.
Interferences
The substances bilirubin F (up to 19.7 mg/dL), bilirubin C (up to 21 mg/dL), hemoglobin (up to 500 mg/dL), lipid factor (up to 1.0%), and rheumatoid factor (up to 459 U/mL) did not interfere with the SeraSpot ® Anti Borrelia IgG and IgM assay (data not shown).
Automatic processing
The correlations between the signal intensities received from manual versus automatic test performance for the single Borrelia specific antigens in the SeraSpot 
DISCUSSION
Microarrays and multiplex tests in laboratory diagnosis
The first microarrays were already developed in the 1990s as screening platforms for genomic analyses based on hybridization reactions [15] . In the following years, the microarray format was adapted to the analysis of proteins, whereby glass slides were the preferred carrier matrix for the protein spots [16] [17] [18] . The first approaches to use microtitration plates as carriers for microarrays were described by Matson et al. in 2001 with their development of a "Microarray-based Cytokine immunosorbent assay" [20] . The SeraSpot ® microarray platform also uses conventional microtitration plates for printing of antigen spots. Following the immune reaction a precipitating chromogenic substrate produces the signals to be evaluated by a reader with a camera system. Bead-based multiplex array technologies were introduced in 1997 with the XMap ® technology by Luminex Corporation. The solid phase of this method is represented by polystyrol beads coated with 2 fluorescent dyes that enable simultaneous identification of bead class and parameter specificity. Mixtures of beads with different parameters are combined for multiplex analyses. Measurement is based on a laser detection system in a flow-through cytometric analyzer (Luminex ® Analyzer or similar systems). The bead-based Luminex ® technology is available for different diagnostic applications provided by different suppliers of commercial kits hereof.
Application of SeraSpot
® microarrays and other multiplex tests for Borrelia serology The serodiagnosis of Lyme borreliosis follows a twostep protocol with an initial screening test (usually ELISA) and a subsequent confirmatory test of positively screened samples. Line immunoassays with recombinant Borrelia specific antigens are the most commonly used confirmatory tests for this purpose in most routine diagnostic laboratories. Compared to ELISA, line immunoassays are more laborious with a lesser degree of automation. It therefore seems obvious to use microarrays or other multiplex assays as confirmatory tests in the serodiagnosis of Lyme borreliosis. Bead-based multiplex assays were introduced into Borrelia serology in 2005 and different suppliers actually offer commercial products employing different combinations of recombinant antigens [13] . There suitability to serve as confirmatory test in Lyme serology has recently been evaluated by Gerritzen and Brandt [13] . In the present study, the new microtitration plate based multiplex microarray test system SeraSpot ® Anti-Borrelia was evaluated in order to test if the application of this method as confirmation test is equal to the currently used test. Therefore, the commercially available and established recomBead ® assay was used to estimate sensitivity and specificity of the single Borrelia antigens. The high concordance between the two test systems with different sample panels confirms the suitability of the SeraSpot ® Anti-Borrelia IgG and IgM assays for this purpose, but further studies with clinically defined sera should be performed. Despite the high concordance, discrepancies with respect to single antigens have been detected.
IgG detection The 9 SeraSpot
® borderline but recomBead ® negative samples are characterized by a positive VlsE reaction in both assays. The raw data of the recomBead ® tests reveal a borderline result (cutoff index 0.7) for 1 sample and clearly positive results for the remaining 8 samples with similar or even higher cutoff indices than the SeraSpot ® assay. So, the results are in concordance for these samples with respect to VlsE reaction although different antigen preparations are used (VlsE full length of B. afzelii in the SeraSpot ® and VlsE fusion protein with immunodominant epitopes of different genospecies in the recomBead ® test). The only difference is the final result interpretation. Although VlsE is positive or borderline in both assays, the evaluation criteria for SeraSpot ® produce a borderline result whereas the criteria of recomBead ® interpret the result as negative. According to DIN 58969-44 and MiQ guidelines a confirmatory test in serological Borrelia diagnosis should be interpreted as borderline if one Borrelia specific protein is positive [5, 14] . Since IgG antibodies to VlsE have proven as sensitive markers, especially in early manifestations of Lyme disease, e.g., erythema migrans, neuroborreliosis, a positive VlsE IgG should not be disregarded [6] . Six out of 11 samples were tested SeraSpot ® positive but recomBead ® negative due to an OspC specific reaction in combination with one or more of the other Borrelia specific proteins. Vice versa, 4 samples with SeraSpot ® negative but recomBead ® positive result were also positive due to OspC reactivity. Since OspC is known as an immunodominant protein in the first stage of Lyme disease, it is considered as less useful for the detection of specific IgG antibodies [6, 21] . On the other hand, the occurrence of anti-OspC IgG antibodies is described with a frequency of about 26% in patients with diagnosed Lyme borreliosis [6] . Patients with diagnosed Lyme arthritis develop IgG antibodies to OspC in up to 60% of the cases [22] . Since the samples included in the Lyme borreliosis panel investigated in this study are all derived from patients with clinical suspicion of borreliosis, the SeraSpot ® positive results might not be false in these cases. However, further investigations with clinically defined samples should be performed. SeraSpot ® borderline (n = 7) but recomBead ® positive samples were caused by either p58 or p100 reactivity that was not detected by the SeraSpot ® assay. Since both tests use these proteins from the same genospecies the difference might be mainly caused by differences regarding concentrations of immunoreactants or by conformational differences of the purified recombinant antigens.
IgM detection
Discrepancies between the tests were mainly caused by differences in the OspC reaction. In SeraSpot ® positive, recomBead ® negative samples the OspC of all three genospecies reacted positive in 13 of 23 cases. The OspC reactivities of the recomBead ® positive but SeraSpot ® negative samples (n = 8) are restricted to B. burgdorferi s.s. and Borrelia garinii. Due to the high variability of the membrane protein OspC, cross reactivities between the three genospecies are limited, but do occur, because the sequence homology on the other hand is stated with about 60% between different Borrelia genospecies [6, 21] . Cross reactive antibodies to OspC in RF, Treponema, or EBV positive sera are also described [23] .
Technical aspects
In general, multiplex tests based on bead or microarray technology offer several advantages compared to classical line immunoassays on nitrocellulose strips, e.g., reduced sample and reagent volumes, improved precision, higher degree of automation and easier handling. Despite these general advantages we revealed some technical differences in our laboratory comparison between the recomBead ® test based on the Luminex ® technology and the SeraSpot ® test based on microarray technology. Besides a similar hands-on time for both assays, subsequent measurement of the sample plate is much faster using the Spotsight ® plate reader with camera as compared to the more laborious and susceptible Luminex ® Analyzer with laser technology. Moreover, no additional consumables are needed, e.g., calibrators, for SeraSpot ® test with respect to the reading system. This indirectly influences maintenance efforts concerning the technical equipment (Table 6 ). These differences demonstrate that the SeraSpot ® technology is obviously more suitable for routine laboratories with respect to simplicity of use and robustness of the technical equipment and might therefore represent the next generation of multiplex assays.
CONCLUSION
The new multiplex microarray test system SeraSpot ® Anti-Borrelia IgG/IgM is suitable for serodiagnosis of Lyme borreliosis. The sensitivity and specificity are comparable to a commercially available bead-based multiplex assay (recomBead ® Borrelia). The precision data are comparable to values usually determined for classical ELISA. The test can be run on conventional ELISA processors under routine laboratory conditions. The measuring technique including the software is robust and easy to handle. Further studies with clinically defined samples should be performed in order to prove the sensitivity with respect to the different stages of Lyme borreliosis.
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